NCT05302596CompletedPhase 2
Semaglutide Use in Elderly Obese Patients
Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment
Source: ClinicalTrials.gov · Last updated 17 Apr 2025
Brief summary (registry, in English)
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 21 Mar 2022
- Start date
- 1 Sept 2022
- Primary completion date
- 23 Oct 2023
- Lead sponsor
- State University of New York at Buffalo
- Diseases
- Obesity
- NCT number
- NCT05302596
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 16
- From 1 Sept 2022 to the primary completion date, 23 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous surgical treatment for obesity
- Use of any medication that could interfere with trial results especially weight management drugs
- Participation in any other concurrent interventional clinical trial -
Other illness
- Current diagnosis of weight changing condition including cancer, gastrointestinal conditions or eating disorders
- Diagnosis of type 1 or 2 diabetes
- History of chronic/idiopathic acute pancreatitis
- Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Hepatic disease or cirrhosis
- History of gastroparesis
- History of serious hypersensitivity reaction to these agents
Lab values
- Aspartate Aminotransferase (AST) \> 3X Upper limit of normal (ULN) and/or Alanine aminotransferase (ALT) \> 3X ULN
Other
- GLP-1R agonists use within last 6 months
- Impaired cognitive function (VA-St. Louis University Mental Survey (VA-SLUMS) score ≤ 19)
- Smoking or use of any nicotine products
- Anticipated change in lifestyle (e.g., dietary, exercise or sleeping pattern) other than provided by the study.
- Inability to give informed consent
- Alcoholism
- Patients with retinopathy
Who the study is looking for
- Males and females age: ≥65 years
- BMI ≥30 Kg/m2 AND waist circumference for women: \> 80 cm and for men: \> 90 cm
- Stable body weight (no more than ±3 kg change during the 3 months prior to screening)
- Able to participate in personalized physical activities and dietary instructions.
- Participant must be able to read, write, and understand the English language and be able to provide written consent.
Age in the registry: 65 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Diabetes and Endocrinology Research Center Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.